Earnings summaries and quarterly performance for CONMED.
Executive leadership at CONMED.
PB
Patrick Beyer
Detailed
President and Chief Executive Officer
CEO
AM
Andrew Moller
Detailed
Vice President, Corporate Controller
BL
Brent Lalomia
Detailed
Executive Vice President, Regulatory Affairs, Quality Assurance, Clinical Affairs, and Commercial Operations
EC
Edward Clifford
Detailed
Vice President, Global Manufacturing
HF
Hollie Foust
Detailed
Executive Vice President, General Counsel and Corporate Secretary
JF
John Ferrell
Detailed
Executive Vice President, Human Resources
JP
Johonna Pelletier
Detailed
Treasurer and Vice President, Tax
PS
Peter Shagory
Detailed
Executive Vice President, Strategy and Corporate Development
RG
Richard Glaze
Detailed
Chief Information Officer
SE
Stephan Epinette
Detailed
Vice President and General Manager, International
TG
Todd Garner
Detailed
Executive Vice President, Finance and Chief Financial Officer
Board of directors at CONMED.
Research analysts who have asked questions during CONMED earnings calls.
YL
Young Li
Jefferies
5 questions for CNMD
Also covers: ALC, ARAY, ATEC +8 more
RM
Robbie Marcus
JPMorgan Chase & Co.
4 questions for CNMD
Also covers: ABT, BAX, BDX +10 more
Travis Steed
Bank of America
4 questions for CNMD
Also covers: ABT, AXNX, BAX +20 more
Mike Matson
Needham & Company, LLC
3 questions for CNMD
Also covers: ENOV, ESTA, HAE +16 more
VC
Vik Chopra
Wells Fargo & Company
3 questions for CNMD
Also covers: ALGN, ATEC, ENOV +8 more
FW
Frederick Wise
Stifel
2 questions for CNMD
Also covers: AORT, ATRC, AVNS +13 more
MO
Matthew O'Brien
Piper Sandler
2 questions for CNMD
Also covers: DXCM, ITGR, KMTS
Michael Matson
Needham & Company
2 questions for CNMD
Also covers: AORT, ATRC, ENOV +22 more
RM
Robert Marcus
JPMorgan Chase & Co.
2 questions for CNMD
Also covers: ABT, BAX, BDX +21 more
KS
Kristen Stewart
CL King & Associates
1 question for CNMD
Also covers: AVNS, HAE, IART +3 more
MO
Matthew O'Brien
Piper Sandler & Co.
1 question for CNMD
Also covers: APYX, ATEC, ATRC +18 more
PD
Phillip Dantoin
Piper Sandler
1 question for CNMD
Also covers: ATEC, FNA, PODD +2 more
VC
Vikramjeet Chopra
Wells Fargo & Company
1 question for CNMD
Also covers: ALGN, ATEC, ENOV +9 more
Recent press releases and 8-K filings for CNMD.
CONMED Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance, and Announces Strategic Changes
CNMD
Earnings
Guidance Update
Share Buyback
- CONMED reported Q4 2025 total sales of $373.2 million, an increase of 7.1% in constant currency, and full-year 2025 total sales of $1.375 billion, up 5.1% in constant currency.
- Adjusted diluted EPS for Q4 2025 was $1.43, a 6.7% increase, and full-year adjusted EPS was $4.59, a 10.1% increase.
- For 2026, the company guides full-year reported revenue between $1.345 billion and $1.375 billion (4.5% to 6% constant currency organic growth) and adjusted EPS between $4.30 and $4.45.
- Strategic initiatives include the decision to exit gastroenterology product lines , the suspension of its dividend, and the approval of a $150 million share repurchase authorization.
- The company also announced a CFO transition, with Todd Garner moving to an advisory role after a transition period.
Jan 28, 2026, 9:30 PM
CONMED Announces Q4 and Full Year 2025 Results and 2026 Guidance
CNMD
Earnings
Guidance Update
Share Buyback
- CONMED reported Q4 2025 revenue of $373.2 million and Adjusted Diluted EPS of $1.43, representing 7.9% and 6.7% growth respectively compared to Q4 2024. For the full year 2025, revenue was $1,374.7 million and Adjusted Diluted EPS was $4.59, growing 5.2% and 10.1% respectively over FY 2024.
- The company provided 2026 financial guidance, projecting Total Reported Revenue between $1,345 million and $1,375 million and Total Adjusted EPS between $4.30 and $4.45.
- CONMED announced a $150 million share buyback program and an intent to exit gastroenterology to sharpen focus on core platforms like minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.
Jan 28, 2026, 9:30 PM
CONMED Reports Q4 and Full Year 2025 Results, Issues 2026 Guidance, and Announces Strategic Shifts
CNMD
Earnings
Guidance Update
Share Buyback
- CONMED reported Q4 2025 total sales of $373.2 million, an increase of 7.9% (7.1% in constant currency), and full-year 2025 sales of $1.375 billion, up 5.2% (5.1% in constant currency).
- Adjusted diluted EPS for Q4 2025 was $1.43, a 6.7% increase, and full-year 2025 adjusted diluted EPS was $4.59, a 10.1% increase.
- For 2026, the company guides reported revenue between $1.345 billion and $1.375 billion (4.5% to 6% constant currency organic growth) and adjusted EPS between $4.30 and $4.45.
- CONMED announced a strategic decision in December to exit its gastroenterology product lines, which is expected to improve the long-term consolidated growth margin profile by approximately 80 basis points.
- The company also suspended its dividend and approved a $150 million share repurchase authorization; additionally, Todd Garner will transition from CFO to an advisory role, with a search for a new CFO underway.
Jan 28, 2026, 9:30 PM
CONMED Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Announces Strategic Portfolio Changes
CNMD
Earnings
Guidance Update
M&A
- CONMED reported Q4 2025 total sales of $373.2 million, a 7.9% year-over-year increase, and full-year sales of $1.375 billion, up 5.2% as reported. Adjusted diluted EPS was $1.43 for Q4 2025 (up 6.7%) and $4.59 for the full year 2025 (up 10.1%).
- The company announced a strategic decision to exit its gastroenterology product lines, which is expected to improve the long-term consolidated growth margin profile by approximately 80 basis points.
- CONMED provided 2026 full-year guidance, projecting reported revenue between $1.345 billion and $1.375 billion (representing 4.5% to 6% constant currency organic growth) and adjusted EPS between $4.30 and $4.45.
- To enhance shareholder value, the board suspended the dividend and approved a $150 million share repurchase authorization.
- Operational improvements include significant progress in resolving sports medicine supply chain constraints, with backorder value and SKUs at a three-year low by the end of 2025.
Jan 28, 2026, 9:30 PM
CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
CNMD
Earnings
Guidance Update
- CONMED Corporation reported sales of $373.2 million for Q4 2025, an increase of 7.9% year-over-year, and full-year 2025 sales of $1,374.7 million, up 5.2% year-over-year.
- For Q4 2025, adjusted diluted net earnings per share were $1.43, compared to $1.34 in Q4 2024. For the full-year 2025, adjusted diluted net earnings per share were $4.59, compared to $4.17 in 2024.
- The company expects full-year 2026 reported revenue to be between $1.345 billion and $1.375 billion, and full-year 2026 adjusted diluted net earnings per share in the range of $4.30 to $4.45.
Jan 28, 2026, 9:13 PM
CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results and 2026 Outlook
CNMD
Earnings
Guidance Update
- CONMED Corporation reported fourth quarter 2025 sales of $373.2 million, an increase of 7.9% year-over-year, with adjusted diluted net earnings per share of $1.43.
- For the full-year 2025, sales reached $1,374.7 million, a 5.2% increase year-over-year, and adjusted diluted net earnings per share were $4.59.
- The company provided full-year 2026 guidance, projecting reported revenue between $1.345 billion and $1.375 billion and adjusted diluted net earnings per share in the range of $4.30 to $4.45.
Jan 28, 2026, 9:05 PM
CONMED Provides Preliminary 2026 Guidance and Strategic Updates
CNMD
Guidance Update
M&A
Share Buyback
- CONMED provided preliminary 2026 guidance, projecting revenue between $1.345 billion and $1.375 billion and adjusted EPS between $4.25 and $4.45. This guidance reflects the exit of the GI business in December 2025, which reduces revenue by $78-$82 million and EPS by $0.50, along with an incremental tariff impact of $0.30-$0.35.
- The company is strategically focusing on its high-growth, high-margin platforms: AirSeal, Buffalo Filter (smoke evacuation), and BioBrace (orthopedic soft tissue repair). The GI business divestiture was undertaken to align resources with these core growth drivers.
- CONMED achieved its target of lowering leverage to below three by the end of Q3 2025. The company suspended its dividend in 2025 and announced a shift to share repurchases, contributing $0.07 to the 2026 EPS guidance.
- Key growth drivers include AirSeal, which is expanding into the laparoscopy market where it holds 6%-7% market share, and Buffalo Filter, whose market is projected to grow from $300-$350 million to over $1 billion due to increasing legislation and clinical validation. BioBrace, an FDA-approved tissue repair technology, launched a new delivery device in 2025 and anticipates clinical data publication in 2027.
Jan 12, 2026, 11:00 PM
CONMED Provides 2026 Financial Guidance and Strategic Updates at J.P. Morgan Healthcare Conference
CNMD
Guidance Update
Share Buyback
New Projects/Investments
- CONMED presented its preliminary financial guidance for Full Year 2026 at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026.
- For FY 2026, the company anticipates Total Reported Revenue to be between $1,345M and $1,375M, with Organic Constant Currency growth of ~4% to ~6%.
- Total Adjusted EPS for FY 2026 is projected to be between $4.25 and $4.45.
- CONMED announced a $150M share buyback program and is optimizing its portfolio by exiting gastroenterology to focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.
- The company is leveraging growth drivers such as high-growth, high-margin products including AirSeal, Buffalo Filter, and BioBrace.
Jan 12, 2026, 11:00 PM
CONMED Provides Preliminary 2026 Guidance and Strategic Updates
CNMD
Guidance Update
Share Buyback
M&A
- CONMED provided preliminary guidance for 2026, projecting revenue between $1.345 billion and $1.375 billion and adjusted EPS between $4.25 and $4.45.
- The company announced its exit from the GI business, which is expected to reduce the top line by $78-$82 million and impact EPS by $0.50.
- CONMED achieved its leverage goal of below three by the end of Q3 2025 and is suspending its dividend to allocate $25 million towards share repurchases, contributing a $0.07 EPS tailwind for 2026.
- The company is focusing on high-growth, high-margin platforms including AirSeal, Buffalo Filter, and BioBrace, and anticipates midterm growth in the 4%-9% range.
Jan 12, 2026, 11:00 PM
CONMED Provides Preliminary 2026 Guidance and Strategic Updates
CNMD
Guidance Update
Share Buyback
M&A
- CONMED provided preliminary 2026 guidance, projecting revenue between $1.345 billion and $1.375 billion and adjusted EPS between $4.25 and $4.45.
- The company exited its GI business in December 2025, which is expected to reduce 2026 revenue by $78-$82 million and impact EPS by $0.50.
- CONMED suspended its dividend in 2025 and will reallocate the $25 million to share repurchases, contributing a $0.07 tailwind to 2026 EPS.
- The company achieved its goal of reducing leverage to below three by Q3 2025, one quarter earlier than planned.
- Key growth drivers, including AirSeal and direct smoke evacuation (Buffalo Filter), are expected to achieve high single-digit to double-digit growth.
Jan 12, 2026, 11:00 PM
Quarterly earnings call transcripts for CONMED.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more